The Food and Drug Administration has approved a new immunosuppressive drug that can delay the onset of type 1 diabetes by two years or longer, according to Healthline. Teplizumab, also known by the brand name Tzield, is administered intravenously every 14 days and is approved for adults and children with stage 2 type 1 diabetes. When type 1 diabetes progresses to stage 3, patients become symptomatic and require insulin.
Diabetes researchers hail the drug as a major breakthrough with the potential to prevent irreversible damage and dramatically reduce the disease burden for patients.
Rick Good spent ten years in the newspaper business, including with The News & Observer (Raleigh, NC) and The Greenville News (Greenville, SC). He co-wrote, with Melinda Coleman, Rutledge to Riley: Governors of South Carolina, 1776–Present (Published by The Greenville News), and is the author of Mind Games Trivia #1 (Amazon). He has recently spent 15 years creating original trivia content through Sounds Good Mobile Entertainment and continues that with his new company, SGME Software. He edits The Smart Reader’s money, real estate, and business coverage.
